Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient

Journal of Neurology

Volumn 260, Issue 6, 2013, Pages 1675-1677

  Piscolla, E ^a   Hakiki, B ^a   Pasto L ^a   Razzolini, L ^a   Portaccio, E ^a   Amato, M P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FINGOLIMOD; GADOLINIUM; METHYLPREDNISOLONE;

ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LETTER; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE;

AGE OF ONSET; BRAIN; CHILD; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLASMA EXCHANGE; PROPYLENE GLYCOLS; SPHINGOSINE; YOUNG ADULT;

EID: 84878890677     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6933-z     Document Type: Letter

References (8)

1. Havla JB, Pellkofer HL, Meinl I et al (2012) Rebound of disease activity after withdrawal of Fingolimod (FTY720) treatment. Arch Neurol 69(2):262-264
2. Hakiki B, Portaccio E, Giannini M et al (2012) Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult Scler 18(11):1636-1639
3. Ghezzi A, Rocca MA, Baroncini D et al (2013) Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol 260(1):327-329
4. De Vera A, Kappos L, Zhang-Auberson L et al (2010) Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment. Mult Scler 16(supplement 10):S 295
5. O'Connor PW, Goodman A, Kappos L et al (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76:1858-1865
6. Vellinga MM, Castelijns JA, Barkhof F et al (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70(13):1150-1151 (Pubitemid 351464749)
7. Martinelli V, Cocco E, Capra R et al (2011) Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 77(21):1887-1895
8. Awad A, Stüve O (2009) Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord 2(6):50-61